Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 15Prostatic Neoplasms 13Neoplasms 4Breast Neoplasms 4Vaginal Neoplasms 2Uterine Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Endometrial Clear Cell Adenocarcinoma 2Vulvar Neoplasms 1Stage IA Uterine Sarcoma 1Radiation Injuries 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Obesity 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Lung Neoplasms 1Locally Advanced Cervical Cancer 1Liver Neoplasms 1Fatigue 1Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation 1Endometrial Adenocarcinoma 1Desmoplastic Small Round Cell Tumor 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Breast Carcinoma In Situ 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 18Cisplatin 12Oxaliplatin 7pembrolizumab 6Nivolumab 6Capecitabine 4trametinib 3Fluorouracil 3Bevacizumab 3tremelimumab 2lenvatinib 2durvalumab 2derazantinib 2atezolizumab 2Trastuzumab 2Ramucirumab 2Radiofrequency Ablation 2Panitumumab 2Leucovorin 2Cryosurgery 2zanidatamab 1vandetanib 1tucatinib 1tocilizumab 1telotristat ethyl 1sargramostim 1rucaparib 1regorafenib 1pertuzumab 1milademetan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Biliary Tract Neoplasms × Brachytherapy × Clear all
NCT00924027 2025-09-05

A Study of Patients Receiving High-Dose Rate Brachytherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
43 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Biliary Tract Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡